L Brookman

804 total citations
18 papers, 656 citations indexed

About

L Brookman is a scholar working on Physiology, Organic Chemistry and Pulmonary and Respiratory Medicine. According to data from OpenAlex, L Brookman has authored 18 papers receiving a total of 656 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Physiology, 4 papers in Organic Chemistry and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in L Brookman's work include Asthma and respiratory diseases (6 papers), Advanced Polymer Synthesis and Characterization (4 papers) and Inhalation and Respiratory Drug Delivery (3 papers). L Brookman is often cited by papers focused on Asthma and respiratory diseases (6 papers), Advanced Polymer Synthesis and Characterization (4 papers) and Inhalation and Respiratory Drug Delivery (3 papers). L Brookman collaborates with scholars based in Switzerland, United Kingdom and Germany. L Brookman's co-authors include Peter Goddard, Janet Brown, Günther Hochhaus, Song Ren, John G. Matthews, Yamo Deniz, Charles L. Johnson, Howard Fox, Karel Petrak and John O’Mullane and has published in prestigious journals such as Journal of Controlled Release, Annals of the New York Academy of Sciences and Journal of Allergy and Clinical Immunology.

In The Last Decade

L Brookman

18 papers receiving 611 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
L Brookman Switzerland 11 194 161 151 109 94 18 656
Eva Moelants Belgium 14 35 0.2× 93 0.6× 126 0.8× 71 0.7× 27 0.3× 14 730
Jenny Sörensson Sweden 12 48 0.2× 70 0.4× 237 1.6× 15 0.1× 22 0.2× 14 731
Shenyin Zhu China 19 59 0.3× 109 0.7× 232 1.5× 13 0.1× 20 0.2× 38 942
C. Ropars France 15 309 1.6× 76 0.5× 199 1.3× 34 0.3× 11 0.1× 74 699
Shilin N. Shukla India 18 159 0.8× 98 0.6× 588 3.9× 29 0.3× 24 0.3× 52 1.3k
Claude Vigneron France 14 133 0.7× 67 0.4× 232 1.5× 22 0.2× 6 0.1× 37 791
Roland A. M. J. Claessens Netherlands 18 139 0.7× 114 0.7× 122 0.8× 16 0.1× 31 0.3× 39 923
Cristian Turato Italy 21 71 0.4× 199 1.2× 369 2.4× 13 0.1× 16 0.2× 61 987
Koichiro Tahara Japan 16 48 0.2× 81 0.5× 104 0.7× 22 0.2× 10 0.1× 56 781
Zhendong Zheng China 19 44 0.2× 137 0.9× 377 2.5× 31 0.3× 13 0.1× 82 867

Countries citing papers authored by L Brookman

Since Specialization
Citations

This map shows the geographic impact of L Brookman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by L Brookman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites L Brookman more than expected).

Fields of papers citing papers by L Brookman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by L Brookman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by L Brookman. The network helps show where L Brookman may publish in the future.

Co-authorship network of co-authors of L Brookman

This figure shows the co-authorship network connecting the top 25 collaborators of L Brookman. A scholar is included among the top collaborators of L Brookman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with L Brookman. L Brookman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Pascoe, Steven, Christine Reynolds, Warren Pleskow, et al.. (2011). Safety, tolerability and pharmacokinetics of single escalating doses of indacaterol, a once-daily beta2-agonist bronchodilator, in subjects with COPD. International Journal of Clinical Pharmacology and Therapeutics. 49(2). 153–161. 10 indexed citations
2.
Rivière, Gilles, et al.. (2011). Bioequivalence of a Novel Omalizumab Solution for Injection Compared with the Standard Lyophilized Powder Formulation. Journal of Bioequivalence & Bioavailability. 3(6). 21 indexed citations
3.
Beier, Jutta, Kai Michael Beeh, L Brookman, et al.. (2009). Bronchodilator effects of indacaterol and formoterol in patients with COPD. Pulmonary Pharmacology & Therapeutics. 22(6). 492–496. 36 indexed citations
4.
Lowe, Philip J., et al.. (2007). The Effect of Discontinuing Omalizumab Therapy on Free IgE Concentration. Journal of Allergy and Clinical Immunology. 119(1). S6–S6. 2 indexed citations
5.
Brookman, L, et al.. (2007). Efficacy and safety of single therapeutic and supratherapeutic doses of indacaterol versus salmeterol and salbutamol in patients with asthma. Current Medical Research and Opinion. 23(12). 3113–3122. 16 indexed citations
6.
Budde, Klemens, Robert Schmouder, Björn Nashan, et al.. (2003). Pharmacodynamics of Single Doses of the Novel Immunosuppressant FTY720 in Stable Renal Transplant Patients. American Journal of Transplantation. 3(7). 846–854. 93 indexed citations
7.
Hochhaus, Günther, L Brookman, Howard Fox, et al.. (2003). Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma. Current Medical Research and Opinion. 19(6). 491–499. 154 indexed citations
8.
Brunkhorst, R., Neumayer Hh, Klemens Budde, et al.. (1999). HUMAN SAFETY AND PHARMACOLOGY OF FTY 720. Transplantation. 67(7). S153–S153. 11 indexed citations
9.
Migoya, Elizabeth, Mark T. Marino, Neumayer Hh, et al.. (1999). DOSE SELECTION BY PREDICTION OF HUMAN ORAL CLEARANCE OF FTY 720 USING INTERSPECIES SCALING. Transplantation. 67(7). S153–S153. 2 indexed citations
10.
Porter, John B., et al.. (1998). A Trial to Investigate the Relationship between DFO Pharmacokinetics and Metabolism and DFO‐Related Toxicity. Annals of the New York Academy of Sciences. 850(1). 483–487. 22 indexed citations
11.
Porter, John B., Iman Hassan, Christopher M. Reid, et al.. (1997). Subcutaneous depot desferrioxamine (CGH 749B); Relationship of pharmacokinetics to efficacy and drug metabolism.. UCL Discovery (University College London). 3 indexed citations
12.
Brookman, L, Paul Rolan, I S Benjamin, et al.. (1997). Pharmacokinetics of valsartan in patients with liver disease. Clinical Pharmacology & Therapeutics. 62(3). 272–278. 77 indexed citations
13.
Duval, Martine, L Brookman, Paul Rolan, et al.. (1997). Effect of renal impairment on the pharmacokinetics and pharmacodynamics of desirudin. Clinical Pharmacology & Therapeutics. 62(1). 50–59. 41 indexed citations
14.
Brown, Janet, et al.. (1993). Soluble Polymeric Carriers for Drug Delivery - Part 6: Preparation and Biodistribution of N5-Hydroxyethyl-L-Glutamine-co-L-Glutamic Acid Copolymers in Rats. Journal of Bioactive and Compatible Polymers. 8(1). 51–68. 6 indexed citations
15.
16.
Rolland, Alain, John O’Mullane, Peter Goddard, L Brookman, & Karel Petrak. (1992). New macromolecular carriers for drugs. I. Preparation and characterization of poly(oxyethylene‐b‐isoprene‐b‐oxyethylene) block copolymer aggregates. Journal of Applied Polymer Science. 44(7). 1195–1203. 66 indexed citations
17.
Goddard, Peter, et al.. (1991). R-[N-Acetyl]eglin c:Poly(oxyethylene) Conjugates: Preparation, Plasma Persistence, and Urinary Excretion. Journal of Pharmaceutical Sciences. 80(12). 1171–1176. 5 indexed citations
18.
Goddard, Peter, et al.. (1989). Soluble polymeric carriers for drug delivery. Part 2. Preparation and in vivo behaviour of N-acylethylenimine copolymers. Journal of Controlled Release. 10(1). 5–16. 82 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Eva Moelants Breakdown of academic impact, for papers by Jenny Sörensson Breakdown of academic impact, for papers by Shenyin Zhu Breakdown of academic impact, for papers by C. Ropars Breakdown of academic impact, for papers by Shilin N. Shukla Breakdown of academic impact, for papers by Claude Vigneron Breakdown of academic impact, for papers by Roland A. M. J. Claessens Breakdown of academic impact, for papers by Cristian Turato Breakdown of academic impact, for papers by Koichiro Tahara Breakdown of academic impact, for papers by Zhendong Zheng
Rankless by CCL
2026